Understanding the Suppression of B-Cell Activation by Human Cord Blood-Derived Stem Cells (CB-SCs) through the Galectin-9-Dependent Mechanism | Chapter 3 | Medical Research and Its Applications Vol. 7

Human cord blood-derived stem cells (CB-SCs) display a unique phenotype, with both embryonic and hematopoietic markers that distinguish them from other known types of stem cells, including hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). It was demonstrated that the direct immune modulation of CB-SCs on the activated B cells via the Gal-9-mediated mechanism leads to the marked suppression of B-cell proliferation and phenotypic changes. The Stem Cell Educator therapy was developed among multiple clinical trials based on the immune modulations of multipotent cord blood-derived stem cells (CB-SCs) on different compartments of immune cells, such as T cells and monocytes/macrophages, in type 1 diabetes and other autoimmune diseases. However, the effects of CB-SCs on the B cells remained unclear. To better understand the molecular mechanisms underlying the immune education of CB-SCs, we explored the modulations of CB-SCs on human B cells. CB-SCs were isolated from human cord blood units and confirmed by flow cytometry with different markers for their purity. B cells were purified by using anti-CD19 immunomagnetic beads from human peripheral blood mononuclear cells (PBMCs). Next, the activated B cells were treated in the presence or absence of coculture with CB-SCs for 7 days before undergoing flow cytometry analysis of phenotypic changes with different markers. Reverse transcription-polymerase chain reaction (RT-PCR) was utilized to evaluate the levels of galectin expressions on CB-SCs with or without treatment of activated B cells in order to find the key galectin that was contributing to the B-cell modulation. Flow cytometry demonstrated that the proliferation of activated B cells was markedly suppressed in the presence of CB-SCs, leading to the downregulation of immunoglobulin production from the activated B cells. Phenotypic analysis revealed that treatment with CB-SCs increased the percentage of IgD+CD27− naïve B cells, but decreased the percentage of IgD−CD27+ switched B cells. The transwell assay showed that the immune suppression of CB-SCs on B cells was dependent on the galectin-9 molecule, as confirmed by the blocking experiment with the anti-galectin-9 monoclonal antibody. Mechanistic studies demonstrated that both calcium levels of cytoplasm and mitochondria were downregulated after the treatment with CB-SCs, causing the decline in mitochondrial membrane potential in the activated B cells. Western blot exhibited that the levels of phosphorylated Akt and Erk1/2 signaling proteins in the activated B cells were also markedly reduced in the presence of CB-SCs. CB-SCs displayed multiple immune modulations on B cells through the galectin-9-mediated mechanism and calcium flux/Akt/Erk1/2 signaling pathways. The data advance our current understanding of the molecular mechanisms underlying Stem Cell Educator therapy to treat autoimmune diseases in clinics.

 

Author (s) Details

Wei Hu
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.

Xiang Song
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.

Haibo Yu
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.

Sophia Fan
Throne Biotechnologies, Paramus, NJ 07652, USA.

Andrew Shi
Throne Biotechnologies, Paramus, NJ 07652, USA.

Jingyu Sun
Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ 07030, USA.

Hongjun Wang

Department of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ 07030, USA.

Laura Zhao

Throne Biotechnologies, Paramus, NJ 07652, USA.

Yong Zhao (MD, PhD)
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.Throne Biotechnologies, Paramus, NJ 07652, USA.

 

Please see the book here:- https://doi.org/10.9734/bpi/mria/v7/476